PD62 Economic Evaluation Of Breast Cancer Genomic Testing For Risk Stratification In Brazil’s Private Healthcare Sector
Ivan Zimmermann, Márcia Gisele Santos, Carlos Magliano · 2025
Read PD62 Economic Evaluation Of Breast Cancer Genomic Testing For Risk Stratification In Brazil’s Private Healthcare Sector by Ivan Zimmermann, Márcia Gisele Santos, Carlos Magliano (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12768777.txt.
Description
Ivan Zimmermann, Márcia Gisele Santos, and Carlos Magliano weigh in a 2025 study whether genomic testing for breast cancer pays in Brazil's private health sector. The Oncotype DX test scores recurrence risk and can spare low-risk patients chemotherapy and its harms. Their model tracked patients through health states over a lifetime, drawing trial data for risk and spread.
Testing everyone gained quality-adjusted life years while saving money overall, roughly forty-one thousand dollars per the model's accounting. Narrower uses, such as testing node-positive patients only, also saved while gaining health. Chemo costs and prescribing habits drove the result most.
Catalog record
| CREATOR | Ivan Zimmermann, Márcia Gisele Santos, Carlos Magliano |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |